Source: Pharamceutical Technology

Catamaran Bio: MaxCyte and Catamaran Bio sign strategic platform licence

Cell-engineering company MaxCyte has signed a strategic platform licence (SPL) with biotechnology company Catamaran Bio to support the chimeric antigen... The post MaxCyte and Catamaran Bio sign strategic platform licence appeared first on Pharmaceutical Technology.

Read full article »
Catamaran Bio's Competitors | Catamaran Bio's News | Catamaran Bio's Financials
Stay up-to-date with the latest news on Catamaran Bio
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Alvin Shih's photo - President & CEO of Catamaran Bio

President & CEO

Alvin Shih

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Catamaran Bio